50 Participants Needed

FDG PET/CT Scan for Glioblastoma

SR
Overseen BySoosan Roodbari
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Jonsson Comprehensive Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 4 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.

Do I need to stop my current medications for this trial?

The trial information does not specify whether you need to stop taking your current medications.

Is the FDG PET/CT scan safe for humans?

FDG PET/CT scans, which use a tracer called Fludeoxyglucose F-18, are generally considered safe for humans and are commonly used in medical imaging to assess brain tumors and other conditions.12345

How does the FDG PET/CT scan treatment for glioblastoma differ from other treatments?

The FDG PET/CT scan is unique because it combines imaging techniques to noninvasively assess the metabolic activity of brain tumors, helping to identify the most aggressive parts of glioblastoma. This approach allows for more precise treatment planning compared to traditional methods, which may not provide as detailed a view of tumor metabolism and activity.35678

What data supports the effectiveness of the treatment Fludeoxyglucose F-18, 18F-FDG, Fludeoxyglucose F-18, FDG for glioblastoma?

FDG-PET scans, which use Fludeoxyglucose F-18, are helpful in managing brain tumors like glioblastoma by showing how the tumor uses glucose, which can help doctors make treatment decisions. They are particularly useful for distinguishing between tumor regrowth and tissue damage from radiation, and for monitoring how well a treatment is working.29101112

Who Is on the Research Team?

JC

Johannes Czernin, MD

Principal Investigator

UCLA / Jonsson Comprehensive Cancer Center

Are You a Good Fit for This Trial?

This trial is for patients with high-grade glioma, specifically glioblastoma, who are about to start therapy. They must be able to provide written consent and not have severe psychiatric illnesses. Pregnant or breastfeeding individuals cannot participate.

Inclusion Criteria

I plan to begin treatment.
I have been diagnosed with a high-grade brain tumor.

Exclusion Criteria

Inability to give written consent
Severe psychiatric illness
Breast feeding/pregnancy

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

6-8 weeks
1 visit (in-person)

Treatment

Patients undergo chemotherapy and FDG PET/CT scans to monitor very early therapy response

48 hours
2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Fludeoxyglucose F-18
Trial Overview The study is testing the use of FDG PET/CT scans in detecting early responses to treatment in glioblastoma patients. It aims to see if changes in tumor glucose consumption after starting chemotherapy can indicate how well the treatment is working.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Treatment (FDG PET/CT)Experimental Treatment3 Interventions
Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Jonsson Comprehensive Cancer Center

Lead Sponsor

Trials
373
Recruited
35,200+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+

Published Research Related to This Trial

In a study of 31 patients with adult supratentorial gliomas, FDG PET scans were shown to be a useful tool for assessing tumor progression and treatment response, with higher FDG PET scores correlating with worse clinical outcomes and lower survival rates.
The study involved 137 FDG PET scans and highlighted the need for further research to compare the effectiveness of FDG PET with traditional imaging methods like MRI and CT in managing malignant gliomas.
Correlation of FDG-PET interpretation with survival in a cohort of glioma patients.Pardo, FS., Aronen, HJ., Fitzek, M., et al.[2016]
FDG-PET is particularly valuable in distinguishing between radiation necrosis and recurrent tumors in glioma patients, with this application accounting for 87% of its use in the study of 75 patients.
While FDG-PET is utilized in various clinical settings for managing primary brain tumors, its primary role is in assessing tumor malignancy and evaluating treatment effects, complementing other imaging techniques like MRI and CT.
Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma.Deshmukh, A., Scott, JA., Palmer, EL., et al.[2019]
FDG PET is effective in detecting high-grade gliomas, cerebral lymphomas, and some unexpected brain metastases, despite challenges due to high background glucose uptake in the brain.
Methionine-(11C) PET and fluorine (18F)-labeled radiopharmaceuticals like FET and FDOPA provide more accurate delineation of low-grade gliomas and improve the precision of targeting brain cancers during treatments like stereotactic radiosurgery.
[PET and malignant cerebral tumors].Talbot, JN., Kerrou, K., Gault, N., et al.[2019]

Citations

Correlation of FDG-PET interpretation with survival in a cohort of glioma patients. [2016]
Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. [2019]
[PET and malignant cerebral tumors]. [2019]
Glucose uptake by gliomas after treatment. A positron emission tomographic study. [2019]
18F-FDG-PET/CT. [2016]
Determining the extent of tumor resection at surgical planning with 18F-fluciclovine PET/CT in patients with suspected glioma: multicenter phase III trials. [2022]
High F-18 FDG uptake in a low-grade supratentorial ganglioma: a positron emission tomography case report. [2019]
Diagnostic Performance and Safety of Positron Emission Tomography Using 18F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial. [2023]
[PET-MR in patients with glioblastoma multiforme]. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
Role of Molecular Imaging with PET/MR Imaging in the Diagnosis and Management of Brain Tumors. [2022]
Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma. [2020]
Spectrum Of Brain Abnormalities Detected On Whole Body F-18 FDG PET/CT Scan. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security